文献速递肿瘤 PET/CT

实体瘤检查点抑制剂治疗的患者选择临床特征与影像学预后预测因素

Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-16

本综述概述了实体瘤检查点抑制剂治疗中用于患者选择和疗效预测的影像学方法。PD-L1表达作为生物标志物在不同临床试验中效用不一,约20-25%的患者在PD-L1染色阴性时仍对检查点抑制剂免疫治疗有应答。RECIST等纯形态学标准不足以早期可靠评估肿瘤对生物治疗的应答,代谢信息和抗体PET成像被研究用于分期和疗效评估时的患者分层。

要点

  • PD-L1表达作为疗效预测标志物在不同试验中效用不一,尚无共识。
  • 约20-25%的患者在PD-L1染色阴性时仍对检查点抑制剂免疫治疗有应答。
  • RECIST等纯形态学标准因肿瘤大小变化非早期可靠应答标志而不充分。

核心结论

  • 代谢信息和基于抗体的PET成像已被研究,为分期和疗效评估时的患者最佳分层提供了有力方法。

研究设计与样本

  • 综述,概述实体瘤检查点抑制剂治疗中影像学预后预测因素用于患者选择的临床特征。

主要发现

  • 抗CTLA-4、抗PD-1和抗PD-L1抗体在晚期黑色素瘤及复发或转移性肺癌和肾癌中正成为标准治疗,与标准化疗相比显示出更高和更持久的应答。
  • 约20-25%的患者在PD-L1染色阴性时仍对检查点抑制剂免疫治疗有应答。
  • 实体瘤常用的纯形态学标准(即RECIST)不充分,因为大小变化不是肿瘤对生物治疗应答的早期可靠标志。
  • 科学界要求持续调整免疫相关应答标准(irRC)以克服该问题。

局限性

  • PD-L1表达作为生物标志物的效用在不同临床试验中各异,迄今尚未就PD-L1表达是否为应答和患者选择的理想标志物达成共识。
  • 并非所有患者对免疫检查点抑制剂有应答,因此需要特定生物标志物来指导和监测治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapidly evolving knowledge on tumor immunology and the continuous implementation of immunotherapy in cancer have recently led to the FDA and EMA approval of several checkpoint inhibitors as immunotherapic agents in clinical practice. Anti-CTLA-4, anti-PD-1, and anti-PDL-1 antibodies are becoming standard of care in advanced melanoma, as well as in relapsed or metastatic lung and kidney cancer, demonstrating higher and longer response compared to standard chemotherapy. These encouraging results have fostered the evaluation of these antibodies either alone or in combination with other therapies in several dozen clinical trials for the treatment of multiple tumor types. However, not all patients respond to immune checkpoint inhibitors, hence, specific biomarkers are necessary to guide and monitor therapy. The utility of PD-L1 expression as a biomarker has varied in different clinical trials, but, to date, no consensus has been reached on whether PD-L1 expression is an ideal marker for response and patient selection; approximately 20-25% of patients will respond to immunotherapy with checkpoint inhibitors despite a negative PD-L1 staining. On the other hand, major issues concern the evaluation of objective response in patients treated with immunotherapy. Pure morphological criteria as commonly used in solid tumors (i.e. RECIST) are not sufficient because change in size is not an early and reliable marker of tumor response to biological therapies. Thus, the scientific community has required a continuous adaptation of immune-related response criteria (irRC) to overcome the problem. In this context, metabolic information and antibody-based imaging with positron emission tomography (PET) have been investigated, providing a powerful approach for an optimal stratification of patients at staging and during the evaluation of the response to therapy. In the present review we provide an overview on the clinical characteristics of patient selection when using imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rossi S, Toschi L, Castello A, et al. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017. PMID: 28815334. doi:10.1007/s00259-017-3802-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。